Datavault AI (NASDAQ: DVLT) announced an expansion of its definitive licensing agreement with DataMeds AI Inc., extending the application of its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement aims to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments. It leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring.
Under the revised terms, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions. This replaces the preferred shares originally contemplated for tax optimization purposes. The companies stated that the agreement accelerates the deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This expansion is significant as it moves Datavault AI's technology into a critical and growing sector—healthcare data management. With patients increasingly seeking control over their health data, the ability to securely access, share, and monetize that data represents a paradigm shift. The integration of blockchain technology ensures data integrity and security, while the inclusion of wearable device and IoT population health data opens avenues for personalized medicine and population health management. The behavioral healthcare patent portfolio further suggests applications in mental health and chronic disease management, areas where remote monitoring and data-driven insights are becoming essential.
For the healthcare industry, this development could lead to more efficient data sharing between patients and providers, reduced administrative burdens, and new revenue streams from data tokenization. Patients could potentially earn rewards or compensation for contributing their health data to research or clinical trials. The technology also has implications for pharmaceutical supply chain transparency, extending from distribution to patient outcomes tracking.
Datavault AI’s platform, which includes the Information Data Exchange, enables Digital Twins and the secure attachment of physical objects to immutable metadata, fostering responsible AI use. The company serves multiple industries, including sports & entertainment, biotech, education, fintech, real estate, and energy. The expansion into commercial healthcare aligns with its strategy to apply its data valuation and monetization capabilities across diverse sectors.
For more information, the full press release is available at https://ibn.fm/vBAxH. Additional updates regarding DVLT can be found in the company’s newsroom at https://ibn.fm/DVLT.
The move reflects a broader trend of technology companies entering healthcare to address data interoperability and patient empowerment. As global health and wellness markets expand, such partnerships could set precedents for how health data is valued and exchanged, potentially influencing regulatory frameworks and industry standards. Datavault AI's focus on secure, blockchain-based solutions positions it to capitalize on these shifts, though forward-looking statements in the announcement remind stakeholders of associated risks.
